Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Jun 2026: Trial registered, NCT07627620

The trials

NCT07627620: Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

State
Not started
Phase
Phase 2
People
54 planned
Started
30 Jun 2026
Primary completion
30 Sep 2027
Arms
Camrelizumab combined with famitinib malate and chemotherapy
Results
None posted
  1. 4 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.